

Fred Massoomi, Pharm.D., RPh, BCSCP, FASHP

massoomi@me.com

 [linkedin.com/in/Massoomi](https://www.linkedin.com/in/Massoomi)



Personal

Office Address: 5618 Nicholas Street
Omaha, Nebraska 68132

Mobile: (402) 415-4194

Birth Name: Firouzan Massoomi

Preferred Name: Fred

Date of Birth: July 16, 1966

Place of Birth: Independence, Kansas

Education

Doctor of Pharmacy Degree, University of Kansas School of Pharmacy
Lawrence, Kansas
August 1984 to May 1990

Post-Graduate Training

ACCP Pharmacokinetics Residency; Creighton University / Saint Joseph Hospital
Clinical Pharmacokinetics Service and Laboratory, Omaha, Nebraska
July 1991 to June 1992

ACCP Infectious Disease and Pharmacokinetics Fellowship; Université Laval
Laboratoire de Pharmacocinétique, Québec City, Québec Canada
Selected as Merck Fellow - The Clinical Pharmacokinetics Lab. SUNY at Buffalo
July 1990 to April 1991 (*one year of a two-year program*)

Professional Certifications

Pharmacy Licensures Kansas #11520 Nebraska #10656

Board Certified Sterile Compounding Pharmacist issued July 2020 – Expires December 2027
Board of Pharmacy Specialist (BPS)

Immunization Certification Issued February 2021
American Pharmacists Association

Current Professional Positions

Director of Professional Services and Advancement, **PharmacyStars** 2024 to Present

Senior Consultant, **Visante, Inc.** 2016 to Present

Professional Work Experience

Compounding Compliance Director, Option Care Health Omaha, NE (remote)	2021 to 2023
Pharmacy Operations Coordinator, Nebraska Methodist Hospital Omaha, Nebraska	1996 to 2016
Clinical Pharmacist, Nebraska Methodist Hospital Omaha, Nebraska	1992 to 1996
Staff Pharmacist: Veterans Administration Kansas City, Missouri	1991 to 1994 Part-time
Pharmacy Intern: Home Health Depot Kansas City, Missouri	1989 to 1990 Part-time
Commissioned Officer Student Training Extern Program United States Public Health Service; Indian Health Service, Sells, Arizona	1989 Summer
Pharmacy Intern: Porters' Drug Store Neodesha, Kansas	1986 to 1989 Part-time
Commissioned Officer Student Training Extern Program United States Public Health Service; Indian Health Service, Acoma, New Mexico	1988 Summer
Research Assistant: University of Kansas Department of Medicinal Chemistry	1987 to 1988 Part-time
Pharmacy Clerk: DeFever-Osborn Drug Store Independence, Kansas	1982 to 1984 Part-time

Professional Appointments & Representation

Nebraska Pharmacists Association

Legislative Committee	2014 to Present
President	2014
Board of Directors, member	January 2006 to 2012
Nebraska State Delegate for ASHP	January 2005 to 2008

Omaha Metropolitan Medical Emergency Response System

Co-Chair of Pharmacy Stockpile Committee	November 1998 to present
--	--------------------------

Teaching Experience

Guest Lecturer: Emergency Preparedness School of Pharmacy and Allied Health Professionals Creighton University; Omaha, Nebraska	2012 to 2021
Guest Lecturer: Emergency Preparedness; Pharmaceutical Waste Regulations Compounding Regulations University of Nebraska, School of Pharmacy; Omaha, Nebraska	2010 to 2019

Professional Organizations

Nebraska Pharmacists Association	1992 to Present
American Society of Health-system Pharmacists	1988 to Present

Professional Volunteer Involvement

*Medical Reserve Corps; Easter Nebraska/Western Iowa
-Douglas County Health Department Vaccine Clinics* 2016 to Present

United States Anti-Doping Agency (USADA) Doping Control
US Olympic Swim Trials 2008, 2012, 2016
US Ice Skating Championship 2013

Key International Professional Presentations

“Steps toward Safety for Handling Hazardous Drugs” Invited guest lecturer of ICU Medical for Taiwan Society of Health-System Pharmacists; Taipei, Taiwan, October 2019

“Closed System Transfer Devices: update”. Invited guest lecturer of Equashield for Spain Society of Health-System Pharmacists; Seville, Spain, October 2019

“Closed System Transfer Devices: update”. Invited guest lecturer of ICU Medical for Saudi Oncology Pharmacy Assembly (SOPA); Riyadh, Saudi Arabia September 2019

“Handling Hazardous Drugs: importance of Closed System Transfer Devices”. Invited guest lecturer of ICU Medical; Tokyo, Japan November 2018

“Monoclonal Antibodies, Biologics & Nanotechnology: The Health Risk of Newer Agents”. Invited guest lecturer of BD for International Society Oncology Pharmacy Practice (ISOPP); Shanghai, China March 2018

“Establishing a Hazardous Drug Safety Program” Invited guest of Conception and Innovation for Individualized Oncology Pharmacy Practice, Shanghai, China October 2017

“Hazardous Drugs: Healthcare’s Dirty Little Secret” Invited guest of Pharmaceutical Israeli Society, Tel Aviv, Israel July 2014

“Hazardous Drugs: Minimizing the risks to healthcare providers” Invited guest of ICU Medical. Singapore, Singapore October 2012

“Hazardous Drugs: Best Practices” & “Closed System Transfer Devices: workshop” Quality and Safe Hospital Pharmacy Practice Conference. King Faisal Specialist Hospital and Research Centre. Jeddah, Saudi Arabia May 2012

“Hazardous Drug Management”. ISOPP Annual Meeting; Melbourne, Australia May 2012

“Globalization of Hazardous Drug Handling Best Practices”. Taiwan Society of Health-system Pharmacists Annual Meeting; Taipei, Taiwan September 2011

“Pharmaceutical Waste Impact on the Environment: a practitioner’s point of view.” International Fellowship of Pharmacists annual meeting; Hyderabad, India September 2011

Key Professional Presentations

“Safe Hazardous Drug Handling Standards” American Pharmacy Association Annual Meeting; Sponsor APhA, Orlando, FL 2024

“Taking USP <800> to the next level with Surface Monitoring” speaker. American Society of Health System Pharmacists Midyear Clinical Meeting; Sponsor ASHP, Las Vega, NV 2019

“Examining Sterile Compounding for Health-Systems: A Look Ahead to 2020” speaker. American Society of Health System Pharmacists Midyear Clinical Meeting; Sponsor ProCE, Las Vega, NV 2019

“Surprising facts about USP 800 readiness; what you need to know today” moderator and speaker. American Society of Health System Pharmacists Midyear Clinical Meeting; Sponsor ProCE, Orlando, FL 2017

“Expert Answers: sterile compounding in health systems” American Society of Health System Pharmacists Midyear Clinical Meeting; Sponsor ProCE, Orlando, FL 2017

“Update on sterile compounding regulations in the United States.” American Society of Health System Pharmacists Midyear Clinical Meeting; Sponsor Baxter, Las Vegas, NV 2016

“Ensuring the safety of health care workers: an update on current and future legislative and regulatory activities”, American Society of Health System Pharmacists Midyear Clinical Meeting; Sponsor BD, Orlando, FL 2013

“Hazardous drug best practices: from order to patient” American Society of Health System Pharmacists Midyear Clinical Meeting, Sponsor ICU Medical, New Orleans, LA December 2011

“Defining best practices for pharmaceutical waste management” American Society of Health System Pharmacists Midyear Clinical Meeting, Sponsor Cardinal Health, New Orleans, LA December 2011

“Connect four: employer prospective for managing pharmaceutical waste” American Society of Health System Pharmacists Midyear Clinical Meeting, Las Vegas, NV December 2009

“Unique ways to minimize exposure to hazardous drugs” Moderator. American Society of Health System Pharmacists Annual Meeting, Las Vegas, NV December 2009

“Effective management of pharmaceutical and hazardous waste” Hot Topic. American Society of Health System Pharmacists Annual Meeting, Chicago, IL June 2009

“Proper handling of hazardous drugs: meeting USP <797>, OSHA, & EPA regulations” moderator and speaker. American Society of Health System Pharmacists Clinical Midyear Meeting, BAXA Sponsored, Orlando, FL December 2008

“The role of the pharmacist with emergency preparedness”, speaker, National Association of City and County Health Officials, Region 7 meeting, Denver, CO December 2007

“Safe handling of hazardous drugs” program speaker, Carmel Pharma Sponsor, American Society of Health-system Pharmacists Clinical Midyear, Pharmacists, Las Vegas, NV
December 2007

“Radiological devices in terrorism, pharmacy preparedness” moderator and speaker. American Society of Health-system Pharmacists Clinical Midyear, Pharmacists, Las Vegas, NV
December 2007

“Emergency Preparedness: Management of Pharmaceuticals during an Emergency” moderator and speaker. American Society of Health-system Pharmacists Clinical Midyear; Pharmacists, Anaheim, CA, December 2006

“Implementation strategies for ASHP recommendations for handling hazardous drugs” moderator. American Society of Health-system Pharmacists Clinical Midyear; Pharmacists, Anaheim, CA, December 2006

“Chemical agent preparedness: A rural model” American Society of Health-system Pharmacists Clinical Midyear; Pharmacists, Las Vegas, NV, December 2005

“OMMRS update: pharmaceutical supplies and planning for the city of Omaha” Nebraska Safety Council. Mayors Council, elected county officials; Omaha, NE, February 2004

“Pharmacists involvement in emergency preparedness” moderator and speaker, American Society of Health-system Pharmacists Clinical Midyear; Pharmacists, New Orleans, LA, December 2003

PUBLICATIONS

International Standards Reference

Connor TH, Massoomi F. Environmental monitoring and medical surveillance of health care workers who handle hazardous drugs (HDs). In Mansur J, editor: *Improving Safe Handling Practices for Hazardous Drugs*. Oak Brook, IL: Joint Commission Resources, 2016.

Eisenberg S, Massoomi F. Closed-system drug transfer devices (CSTDs): An introduction. In Mansur J, editor: *Improving Safe Handling Practices for Hazardous Drugs*. Oak Brook, IL: Joint Commission Resources, 2016.

Book Chapter

LeBel M, Massoomi F. Upper Respiratory Tract Infections, Chapter 96, in DiPiro, Talbert, Hayes, Yee, Posey (eds.) *Pharmacotherapy*, Second Edition. Elsevier Publishing. 1992.

Articles

Massoomi F. Overcoming USP <800> Compliance Challenges. **Pharmacy Purchasing and Products**. January 2024: 2-4.

Massoomi F, Burger M. FDA Issues a Critical Safety Communication on Syringes Manufactured in China. **Pharmacy Practice News**. January 2, 2024;1-7.

Massoomi F. State of Pharmacy Compounding Update 2023. **Pharmacy Purchasing and Products**. November 2023; 14.

Massoomi F, Jorgenson J. Environmental Monitoring for Sterile Hazardous Drug Compounding. **Pharmacy Practice News, Special Edition**. June 2023;43-49.

Massoomi F, Jorgenson J. Understanding Compounding Isolation Systems. **Pharmacy Purchasing and Products** November 2022.

Massoomi F. Ask the Expert: USP<800> compliance update: A sneak peek at PP&Ps latest data. **Pharmacy Purchasing and Products** December 2021;18(12): 2-3.

Massoomi F, Eisenberg S, Jorgenson J. Lean thinking for CSTDs. **Pharmacy Practice News Special Edition** 2021: 7-10

Burger M, Massoomi F. IV Insulin Infusions: Is Variation the Enemy of Quality and Safety? **Pharmacy Practice News**. December 2019; 16-19.

Massoomi F. Tips for a Successful USP <800> Cleaning Program. **Pharmacy Purchasing and Products** March 2019;18-24

Massoomi F. Elements of a USP <800> Compliant Cleaning Program. **Pharmacy Purchasing and Products** January 2019;12-16

Jenson MK, Massoomi F, Jorgenson J. Ophthalmic Compounding and Implications Revised United States Pharmacopeia Chapter 797 Standards. **Current Trends Ophthal** 2019;2(1):115-122

Massoomi F. Implement a Comprehensive HD Spill Management Program. **Pharmacy Purchasing and Products** October 2018:8-20

Massoomi F. Choosing Proper Hazardous Drug PPE for USP <800>: Part 2. **Pharmacy Purchasing and Products** July 2018: 4-9

Massoomi F. Choosing Proper Hazardous Drug PPE for USP <800>: Part 1. **Pharmacy Purchasing and Products** June 2018: 24-31

Massoomi F. How Can Pharmacy Maximize the Value of Wipe Analysis? **Pharmacy Purchasing and Products** March 2018:2-6

Jorgenson J, Massoomi F. The NIOSH Vapor Containment Protocol for CSTD Testing. **Pharmacy Purchasing & Products** February 2018: 4-7

Massoomi F, Arruda J. A Closer Look at Prefilled Flush Syringe Safety. **Pharmacy Practice News** February 2018; 1-6

Massoomi F, Kvanz D. USP <800> Requirements for Engineering Controls. **Pharmacy Purchasing & Products** December 2016: 16-22

Connor T, Power L, Massoomi F, Polovich M White Glove Test for Safety: Use caution before buying and wearing gloves intended for handling chemotherapy drugs. **The Joint Commission EC News** March 25 2015;18(3);6-11.

Massoomi F. The Evolution of the CSTD. **Pharmacy Purchasing & Products** February 2015: S1-S12.

Connor T, Power L, Massoomi F, Polovich M. Are gloves and gowns safe for handling chemotherapy? **Pharmacy Purchasing & Products** January 2015:2-3.

Massoomi F, Knolla K. Identifying hazardous drug residue via wipe analysis. **Pharmacy Purchasing & Products** July 2013: 42 - 47.

Massoomi F. Improve Environmental Monitoring Through Outsourcing. **Pharmacy Purchasing & Products** March 2013: 6-11.

Massoomi F. Closed System Transfer Devices: the cost of doing business. **Pharmacy Purchasing & Products** November 2012: 10-16.

Massoomi F. Pharmaceutical waste: is your facility at risk? **PSQH** 2012; 9(5):48-52.

Massoomi F. Flushing away our future: Environmental impact and pharmaceutical waste management. **Industrial Pharmacy** September 2012; issue 35: 6-9.

Greisen D, Massoomi F. Assessing vial transfer devices for hazardous drugs. **Pharmacy Purchasing & Products** November 2011: 104-6

Gonzalez R, Massoomi F. Manufacturers' recommendations for handling spilled hazardous drugs. **Am J Health-Syst Pharm** 2010;67:1985-86 (with electronic attachment)

Gonzalez R, Massoomi F, Neff B. Emergency Use Authorization of Peramivir. **Am J Health-Syst Pharm** 2009;66:162-163

Nygaard A, Nelson AS, Pick A, Danekas P, Massoomi F, et al. Inter-rater reliability in the evaluation of a thrombosis risk assessment tool. **Hospital Pharmacy** 2009;44:1089-94

Massoomi F. Assessing vial transfer devices for handling hazardous drugs. **Pharmacy Purchasing & Products** 2009, March: 18 - 22

Massoomi F. Pharmaceutical Waste Management: a field report for Health-system pharmacy; **Pharmacy Purchasing & Products** 2008, October: supplement

Massoomi F, Neff B, Pick A, Danekas P. Implementation of a safety program for handling hazardous drugs in a community hospital. **Am J Health-Syst Pharm.** 2008;65:861-5

Massoomi F. Going Green: a field report for Health-system pharmacy; Pharmacy's Role in Environmental Stewardship. **Pharmacy Purchasing & Products** 2008, July: supplement

Massoomi F, Neff B. Implementing a personnel surveillance program for hazardous drug safety. **Pharmacy Purchasing & Products** April 2008: 2-5

Bennett, J, Massoomi, F. Establishing a Formal Cleanroom Cleaning Strategy. **Pharmacy Purchasing & Products** 2007, July:12-14.

Massoomi F. Establishing a Hazardous Drug Safety Program. **Pharmacy Purchasing & Products** 2007, May:18-19.

Candy T, Massoomi F. A Review of USP Chapter 797. **Tech Topics** 2007;12:1-36.

Pick A, Massoomi F, Danekas P, Neff B, Stoysich A. A Safety Assessment Tool for Formulary Candidates. **Am J Health-Syst Pharm** 2006, 63:1269-72

Massoomi F. Pharmacists in the Omaha Metropolitan Medical Response System. **Am J Health-Syst Pharm** 2005;62:1290-8

Stoysich AM, Massoomi F. Automatic interchange of the ACE inhibitors: decision-making process and initial results. **Formulary** 2002;37:41-44.

Stoysich AM, Massoomi F, Danekas PL, Williams TL, Ryschon KL. A review of two anticoagulant monitoring devices. **J Pharm Technol** 2001;17:201-06.

Stoysich AM, Massoomi F, Danekas PL. Use of a weight- and diagnosis-based heparin dosing nomogram in community hospital. **Formulary** 2001;36:363-366.

Massoomi F. Formulary management: antibiotics and therapeutic interchange. **Pharmacy Practice Management Quarterly** 1996;16(3):11-17.

Massoomi F, Mathews HM, Destache C. Effect of seven fluoroquinolones on the determination of serum creatinine by the picric acid and enzymatic methods. **The Annals of Pharmacotherapy** 1993;15(5):350-53.

Massoomi F, Savage JL, Destache C. Omeprazole: A comprehensive review. **Pharmacotherapy** 1993;13(1):46-59.

LeBel M, Massoomi F, Bisson C. Positive interference with serum creatinine determination by cefpirome, but no effect with cefepime. **Pharmacotherapy** 1991.

Massoomi F, Haley C. 1990 update of the manufacturing listing. **J Pharmacy Technology** 1990;60:151-165.

Massoomi F, Howard P. Nifedipine and the gastrointestinal transfer system. **Kansas Pharmacy** 1990;64:10-12.

Evens D, Bauck L, Courtright J, Massoomi F, et al. Pharmacy as a profession, Part I. **Wellcome Trends in Pharmacy** 1988;8:1-4.

Presented Abstracts

Nikola J, Gonzalez G, Massoomi F. Opening up the CSTD. 2015 ASHP Midyear Clinical Meeting; New Orleans, LA 2015

Berdi F, Gonzalez R, Massoomi F. Evaluation of syringes used for compounding hazardous drugs and the contamination risks to healthcare personnel. ASHP Midyear Clinical Meeting; Anaheim, CA 2014

Koraleski M, Massoomi F, Zock M. Evaluation of FDA-Approved ONB Closed-System

Transfer Devices Utilizing Cyclophosphamide as a Marker. American Society of Health-System Pharmacists Clinical Midyear Meeting, Orlando, FL 2013

Pfeifer C, Fuller P, Koraleski M, Massoomi F. pH Liquid Integrity Test of FDA-Approved ONB Closed-System Transfer Devices. American Society of Health-System Pharmacists Clinical Midyear Meeting, Orlando, FL 2013

Knolla K, Greisen D, Massoomi F, Time and motion study of 5 closed system transfer devices for IV chemotherapy drug compounding and administration. American Society of Health-System Pharmacists Clinical Midyear Meeting, New Orleans, LA 2011

Neitzel J, Stoysich A, Danekas P, Massoomi F, et. Al. Drug Utilization of a therapeutic interchange involving angiotensin II receptor blocking agents. American Society of Health-System Pharmacists Clinical Midyear Meeting, Las Vegas, NV 2007

Stoysich A, Nygaard A, Ryschon K, Pick A, Danekas P, Massoomi F. Utilization and reliability in evaluating a thrombus risk assessment tool. American Society of Health-System Pharmacists Clinical Midyear Meeting, Las Vegas, NV 2007

Higgins M, Neitzel J, Massoomi F, Danekas P, Pick A. Potential reimbursement loses with implementation of new CMS guidelines for the use of EPO in cancer and related neoplasm conditions. American Society of Health-System Pharmacists Clinical Midyear Meeting, Las Vegas, NV 2007

Massoomi F, Danekas P, Pick A, Bennett J, Nygaard A. Implementation Strategies for Preventing Occupational Exposures to Hazardous Drugs Based on ASHP Recommendations in a Community Based Hospital. American Society of Health-System Pharmacists Clinical Midyear Meeting, Anaheim, CA 2006

Bennett J, Neff W, Massoomi F, Danekas P, Hemrick K. Comparison of Sterile to Non-Sterile Gloves for Compounding Low and Medium-risk Sterile Products. American Society of Health-System Pharmacists Clinical Midyear Meeting, Anaheim, CA 2006

Stoysich A, Pick A, Danekas P, Massoomi F, Borchert K. Minimization of Utilization of Meperidine Following Health Care Provider Education. American Society of Health-System Pharmacists Clinical Midyear Meeting, Anaheim, CA 2006

Danekas P, Borchert K, Nygaard A, Neff W, Massoomi F, Ponniah C. Drug Use Evaluation of Bivalirudin in a Community Hospital Cath Lab. American Society of Health-System Pharmacists Clinical Midyear Meeting, Anaheim, CA 2006

Pick A, Stoysich A, Danekas P, Massoomi F. Case Report: Argatroban and Warfarin Successful in Multiple Hypercoagulable States. American Society of Health-System Pharmacists Clinical Midyear Meeting, Anaheim, CA 2006

Zack K, Pick A, Danekas P, Massoomi F, Borchert K. Dosing and Safety of Intravenous Iron in a Community Hospital and Outpatient Infusion Center. American Society of Health-System Pharmacists Clinical Midyear Meeting, Anaheim, CA 2006

Massoomi F, Danekas P, Pick A, Bennett J. Implementation Strategies for Preventing Occupational Exposures to Hazardous Drugs Based on NIOSH Recommendations in a

Community Based Hospital. American Society of Health-System Pharmacists Clinical Midyear Meeting, Las Vega, NV 2005

Massoomi F, Danekas P, Pick A, Bennett J. Cost Associated with Implementing USP 797 Recommendations in a Community Based Hospital. American Society of Health-System Pharmacists Clinical Midyear Meeting, Las Vega, NV 2005

Massoomi F, Danekas P, Pick A. Safe Assessment Formulary Evaluation: SAFE Tool. American Society of Health-system Pharmacists Clinical Midyear Meeting; Orlando, FL 2004

Neff B, Massoomi F, Danekas P. Experience with West Nile Virus Immune Globulin. American Society of Health-system Pharmacists Clinical Midyear Meeting; Orlando, FL 2004

Danekas P, Massoomi F, Bennett J. A new approach to managing patients, a new pharmacy model. American Society of Health-system Pharmacists Clinical Midyear Meeting; New Orleans, LA 2003

Candy T, Massoomi F. Impact of a pharmacy in a community hospital for intravenous Protonix® utilization. Mid-West Residency Conference, Little Rock, AR 2002

Ashley LS, Stoysich AM, Massoomi F, Danekas PL. Clinical and cost evaluation following a therapeutic interchange for sustained release diltiazem products. American Society of Health-system Pharmacists Clinical Mid-year Meeting; New Orleans, LA 2001

Danekas PL, Neff WJ, Massoomi F, Stoysich AM. Automatic renal dose adjustment program at a community hospital. American Society of Health-system Pharmacists Clinical Mid-year Meeting; New Orleans, LA 2001

Stoysich AM, Sarte C, Massoomi F, Danekas PL. Is there an acute interaction between warfarin and COX-2 inhibitors? American Society of Health-system Pharmacists Clinical Mid-year Meeting; New Orleans, LA 2001

Bennett GA, Stoysich AM, Massoomi F, Danekas PL. Accuracy, precision, clinical correlation, ease of use and cost comparison of 2 portable coagulation monitoring devices. American Society of Health-system Pharmacists Clinical Mid-year Meeting; Las Vegas, NE 2000

Bocher KC, Stoysich AM, Massoomi F; Formulary Management: Automatic Therapeutic Interchange and Angiotensin Converting Enzyme Inhibitors. American Society of Health-system Pharmacists Clinical Mid-year Meeting; Las Vegas, NE 2000

Therkildsen DJ, Stoysich, AM, Massoomi F, Neff W, Ryschon K. Assessment of electrical stimulation adjunctive therapy for antiemetic control. American Society of Health-system Pharmacists; Las Vegas, NE 2000

Stoysich A, Massoomi F, Danekas P. Weight Based Heparin Program for a Community Based Hospital. American College of Clinical Pharmacy Annual Meeting. Kansas City, MO 1999

Massoomi F, Danekas P, Destache C. Determining creatinine clearance in the obese. American College of Clinical Pharmacy Annual Meeting. Orlando, FL 1995

Danekas P, Massoomi P. Famotadine-induced hepatitis confirmed by re-challenge. American College of Clinical Pharmacy Annual Meeting. Orlando, FL 1995

Destache CJ, Vanden Bosch AC, Massoomi F, Bertoni R. Predictive performance of phenytoin using Bayesian and Martin-Tozer methods. American College of Clinical Pharmacy Annual Meeting. Toronto, Ontario Canada. 1992

LeBel M, Massoomi F, Bisson C. Positive interference with serum creatinine determination by cefpirome, but no effect with cefepime. 17th International Congress of Chemotherapy. Berlin, Germany; June 1991.

Key Internet Based Continuing Education Programs

‘Alphabet of Compliance: USP, NIOSH, FDA, DEA, and TJC update’: Pharmacy Stars and Visante. 2020

“Waypoint: USP <800> Road to Compliance” Series of 18; Visante, Inc. 2017 to 2019

“USP 800 and The Impact to Healthcare Facilities”: Pharmacy Advisor.com; Sponsor Baxter 2014

“Update on Pharmaceutical Waste Management Regulations and Practices” Pharmacy Advisor.com; Sponsor Baxter 2013

“LEANING Up the Hazardous Drug Process” Sponsor VHA/Novation as part of the Oncology Program 2013

“Pharmaceutical Waste Management Update” in conjunction with EPA Update. Sponsor Carefusion 2012

“Hazardous Drug Best Practice Standards” Sponsor VHA/Novation as part of the Oncology Program 2012

“Update on Hazardous Drug Program Pearls for Hospitals” Sponsor VHA/Novation as part of the Oncology Program 2011

“Pharmaceutical Waste Management: are we there yet?” Sponsor Pharmacy Onesource, 2011

“Establishing a Hazardous Drug Program” Sponsor VHA/Novation as part of the Oncology Program, 2010

“Pharmaceutical Waste Management: Cradle to Grave Management” Pharmacy Advisor.com; Sponsor Baxter, 2009

“Pharmaceutical Waste Management: Issues and Options for Health Systems” Sponsor American Society of Health-System Pharmacists Foundation Advantage, 2007

“Disaster and Terrorism Response: Emergency Preparedness for Pharmacists and Health-System Pharmacy Departments” Sponsor American Society of Health-System Pharmacists Foundation Advantage, 2006

Professional TV Appearances

A Healthy Debate: Medical Marijuana, participant interviewee KETV 2008
H1N1 vaccine arrival and distribution, interviewee, KETV: 2009
Drug Supplies for a terrorist event, Interviewee. KETV: 2003
OMMRS Mayor's Press Conference, Presenter. KETV, KMTV, FOX: 2003
Drug Shortages, Interviewee. KETV: 2003

Honors and Awards

<i>Nebraska Pharmacists Association, President</i>	2014
<i>Invited witness for the House of Representatives; Committee on Natural Resources Subcommittee on Insular affairs, Oceans and Wildlife. "Overdose: How Drugs and Chemicals in Water Supplies and the Environment are Harming our Fish and Wildlife"</i> Presented at the House of Representative in Washington DC	2009
<i>Innovative Pharmacist of the Year</i> Presented by the Nebraska Pharmacists Association	2007
<i>Fellow of the American Society of Health System Pharmacists</i> Presented by the American Society of Health System Pharmacists	2006
<i>Volunteer of the Year in Healthcare: OMMRS Planning</i> Presented by the United Way of the Midlands	2006
<i>Nebraska Health-System Pharmacist of the Year</i> Presented by the Nebraska Pharmacists Association	2004
<i>Heartland Hero: OMMRS Planning</i> American Red Cross	2003
